Skip to main content

Table 2 The 19-miRNA prognostic signature and its characteristics

From: Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets

Signatures miRNA ID Top 100 survival significant miRNAs selected by DDSS-1D DDSS-1D ( with 10-fold cross validation) DDSS-2D
Log-rank P-value Survival pheno-typea Cut-off Average expression in subgroup 1 Average expression in subgroup 2 P-value in M-W test P-value Confidence level CV of cutoffb Frequency of synergistic gene pairs (P<0.05)
hsa-miR-483-5p 9.31E-06 2 4.71 4.42 5.05 1.13E-63 3.50E-04 1 0.65% 50
hsa-miR-148a 5.07E-05 1 6.33 6.89 5.84 2.44E-78 6.66E-05 1 0.00% 57
hsa-miR-98 1.49E-04 1 4.70 5.01 4.48 2.50E-70 5.20E-03 1 0.75% 50
hsa-miR-494 1.50E-04 2 6.45 5.70 7.23 2.55E-73 8.10E-04 1 0.25% 51
hsa-miR-575 1.82E-04 2 4.91 4.67 5.30 3.01E-77 7.50E-04 1 0.06% 56
hsa-miR-136 3.02E-04 2 4.73 4.40 4.97 7.18E-39 1.40E-02 0.99995 0.48% 53
hsa-miR-143 3.33E-04 2 4.99 4.46 5.29 8.21E-28 3.40E-03 0.99993 0.61% 52
hsa-miR-214 9.47E-04 2 5.29 4.68 5.65 1.90E-43 9.10E-03 1 0.35% 59
hsa-miR-324-3p 1.36E-03 2 5.79 5.21 6.03 1.25E-20 7.20E-03 1 0.01% 51
hsa-miR-34a 2.11E-03 2 5.92 5.59 6.46 7.90E-76 3.90E-03 1 0.03% 54
hsa-miR-377 2.08E-03 2 4.19 4.12 4.57 5.80E-31 2.00E-02 0.99989 0.31% 51
hsa-miR-10b 2.76E-03 1 5.59 6.61 5.29 2.58E-58 1.20E-02 0.99996 0.30% 57
hsa-miR-192 2.99E-03 1 4.48 4.78 4.34 5.70E-75 3.30E-03 1 0.03% 52
hsa-miR-134 3.67E-03 2 5.01 4.53 5.24 9.11E-22 3.30E-03 1 0.11% 54
hsa-miR-365 3.85E-03 1 4.95 5.54 4.78 9.72E-27 1.10E-02 1 0.07% 51
hsa-miR-424 3.89E-03 1 4.90 5.58 4.69 3.70E-52 2.30E-02 0.99934 0.60% 53
hsa-miR-205 7.57E-03 1 4.48 5.75 4.20 1.28E-60 1.20E-02 0.99984 0.06% 59
hsa-miR-181d 9.38E-03 1 4.24 4.51 4.18 5.80E-31 1.24E-02 0.99966 0.05% 60
  1. a1:: tumor suppressor-like expression pattern 2: pro-oncogenic–like expression miRNA phenotype; defined by the relationships between predicted disease risks and expression level values of the miRNA in cancer tissue (Methods)
  2. bCV: coefficient of variation
  3. *Fold change value is calculated as the ratio of the mean expression values of a miRNA of high-risk patients versus that of low-risk patients. 11 novel HG-SOC outcome predictive miRNAs are highlighted in boldface.